Published 2024
| Version v1
Publication
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)
Creators
- Catalano, Fabio
- Brunelli, Matteo
- Signori, Alessio
- Rescigno, Pasquale
- Buti, Sebastiano
- Galli, Luca
- Spada, Massimiliano
- Masini, Cristina
- Galuppini, Francesca
- Vellone, Valerio Gaetano
- Gaggero, Gabriele
- Maruzzo, Marco
- Merler, Sara
- Vignani, Francesca
- Cavo, Alessia
- Bimbatti, Davide
- Milella, Michele
- Dei Tos, Angelo Paolo
- Sbaraglia, Marta
- Murianni, Veronica
- Damassi, Alessandra
- Cremante, Malvina
- Maffezzoli, Michele
- Llaja Obispo, Miguel Angel
- Banna, Giuseppe Luigi
- Fornarini, Giuseppe
- Rebuzzi, Sara Elena
Contributors
Others:
- Catalano, Fabio
- Brunelli, Matteo
- Signori, Alessio
- Rescigno, Pasquale
- Buti, Sebastiano
- Galli, Luca
- Spada, Massimiliano
- Masini, Cristina
- Galuppini, Francesca
- Vellone, Valerio Gaetano
- Gaggero, Gabriele
- Maruzzo, Marco
- Merler, Sara
- Vignani, Francesca
- Cavo, Alessia
- Bimbatti, Davide
- Milella, Michele
- Dei Tos, Angelo Paolo
- Sbaraglia, Marta
- Murianni, Veronica
- Damassi, Alessandra
- Cremante, Malvina
- Maffezzoli, Michele
- Llaja Obispo, Miguel Angel
- Banna, Giuseppe Luigi
- Fornarini, Giuseppe
- Rebuzzi, Sara Elena
Description
: Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months). Areas covered: The current study includes extensive immunohistochemical analysis of T-lineage markers (CD3, CD4, CD8, CD8/CD4 ratio), macrophages (CD68), ph-mTOR, CD15 and CD56 expression on tumor cells, and PD-L1 expression, on an increased sample size including 161 tumor samples (113 patients) compared with preliminary presented data. Responders' tumor tissue (n = 90; 55.9%) was associated with lower CD4 expression (p = 0.014), higher CD56 expression (p = 0.046) and higher CD8/CD4 ratio (p = 0.030). Expert opinion/commentary: The present work suggests the regulatory role of a subpopulation of T cells on antitumor response and identifies CD56 as a putative biomarker of immunotherapy efficacy.
Additional details
Identifiers
- URL
- https://hdl.handle.net/11567/1174395
- URN
- urn:oai:iris.unige.it:11567/1174395
Origin repository
- Origin repository
- UNIGE